1. Home
  2. KMDA vs FTH Comparison

KMDA vs FTH Comparison

Compare KMDA & FTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Kamada Ltd.

KMDA

Kamada Ltd.

SELL

Current Price

$8.15

Market Cap

460.3M

Sector

Health Care

ML Signal

SELL

Logo Faeth Therapeutics Inc. Common Stock

FTH

Faeth Therapeutics Inc. Common Stock

HOLD

Current Price

$9.05

Market Cap

507.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
KMDA
FTH
Founded
1990
1999
Country
Israel
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
460.3M
507.8M
IPO Year
2013
2021

Fundamental Metrics

Financial Performance
Metric
KMDA
FTH
Price
$8.15
$9.05
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
3
15
Target Price
$13.75
★ $56.15
AVG Volume (30 Days)
103.5K
★ 691.0K
Earning Date
11-09-2026
11-03-2026
Dividend Yield
★ 6.86%
N/A
EPS Growth
★ N/A
N/A
EPS
★ N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$12.75
N/A
Revenue Next Year
$13.63
N/A
P/E Ratio
$24.59
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$6.60
$8.58
52 Week High
$9.35
$42.14

Technical Indicators

Market Signals
Indicator
KMDA
FTH
Relative Strength Index (RSI) 56.89 24.63
Support Level $7.99 N/A
Resistance Level $8.62 $21.97
Average True Range (ATR) 0.25 1.92
MACD 0.09 -0.64
Stochastic Oscillator 88.61 3.21

Price Performance

Historical Comparison
KMDA
FTH

About KMDA Kamada Ltd.

Kamada Ltd is a drug-focused, plasma-derived protein therapeutics company. It is involved in the business of developing, producing, and marketing specialty therapeutics using protein purification proprietary technology. Its product portfolio consists of Glassia, Bramitob, Foster, Ixiaro, Factor-IX, and others. The company has two segments namely, the Proprietary Products segment and the Distribution segment. It derives the majority of its revenue from the Proprietary products segment. The firm categorizes its products in Lung Disease, Vaccines, Haemophilia, Immunoglobulins, Critical care, and Diagnostics.

About FTH Faeth Therapeutics Inc. Common Stock

Faeth Therapeutics Inc is a clinical-stage biotechnology company focused on improving outcomes for cancer patients through multi-node inhibition of critical oncogenic pathways. The company's principal program is PIKTOR, an investigational all-oral combination of serabelisib and sapanisertib in development for endometrial and breast cancer.

Share on Social Networks: